Abstract
Statins are a diverse group of drugs, which share the ability to inhibit HMG CoA reductase and thereby the conversion of acetoacetyl CoA to mevalonate, the rate-limiting step in cholesterol biosynthesis. By inhibiting mevalonate production statins inhibit the pathway leading to the generation of farnesylpyrophosphate and geranylgeranyl pyrophosphate, two pyrophosphates that are critical for the induction of a variety of signal transduction pathways, which promote a cascade of events leading to endothelial dysfunction, inflammation, proliferation, apoptosis and other effects important for atherogenesis. Even though statins share a common mode of action they differ by several features like chemical structure, affinity towards HMG CoA reductase and their relative lipophilicity. These features translate into marked differences in LDL cholesterol lowering efficacy, pharmacokinetic properties and differences in lipophilicity associated with different tissue affinity and penetration. Rosuvastatin and atorvastatin produce the greatest percentage change in LDL cholesterol. Fluvastatin and pravastatin are less prone to drug interactions, because they are not metabolized through the CYP450 3A4 system. The hydrophilic pravastatin does not inhibit proliferation and migration of vascular smooth muscle cells. Data from clinical trials with statins suggest that the efficacy in LDL cholesterol lowering plays the overriding role in cardiovascular event reduction.
Keywords: HMG CoA reductase inhibitors, pleiotropic effects, cardiovascular disease prevention, LDL cholesterol lowering, lipids, statins
Current Drug Therapy
Title: Statins: Are They All the Same?
Volume: 1 Issue: 2
Author(s): Walter F. Riesen
Affiliation:
Keywords: HMG CoA reductase inhibitors, pleiotropic effects, cardiovascular disease prevention, LDL cholesterol lowering, lipids, statins
Abstract: Statins are a diverse group of drugs, which share the ability to inhibit HMG CoA reductase and thereby the conversion of acetoacetyl CoA to mevalonate, the rate-limiting step in cholesterol biosynthesis. By inhibiting mevalonate production statins inhibit the pathway leading to the generation of farnesylpyrophosphate and geranylgeranyl pyrophosphate, two pyrophosphates that are critical for the induction of a variety of signal transduction pathways, which promote a cascade of events leading to endothelial dysfunction, inflammation, proliferation, apoptosis and other effects important for atherogenesis. Even though statins share a common mode of action they differ by several features like chemical structure, affinity towards HMG CoA reductase and their relative lipophilicity. These features translate into marked differences in LDL cholesterol lowering efficacy, pharmacokinetic properties and differences in lipophilicity associated with different tissue affinity and penetration. Rosuvastatin and atorvastatin produce the greatest percentage change in LDL cholesterol. Fluvastatin and pravastatin are less prone to drug interactions, because they are not metabolized through the CYP450 3A4 system. The hydrophilic pravastatin does not inhibit proliferation and migration of vascular smooth muscle cells. Data from clinical trials with statins suggest that the efficacy in LDL cholesterol lowering plays the overriding role in cardiovascular event reduction.
Export Options
About this article
Cite this article as:
Riesen F. Walter, Statins: Are They All the Same?, Current Drug Therapy 2006; 1 (2) . https://dx.doi.org/10.2174/157488506776930969
DOI https://dx.doi.org/10.2174/157488506776930969 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prostacyclin Analogues: Prevention of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Plant Polyphenols and Tumors: From Mechanisms to Therapies, Prevention, and Protection Against Toxicity of Anti-Cancer Treatments
Current Medicinal Chemistry Aquaporin-1 and Sodium-Hydrogen Exchangers as Pharmacological Targets in Diabetic Atherosclerosis
Current Drug Targets Cardiovascular Magnetic Resonance for Evaluation of Heart Involvement in ANCA-Associated Vasculitis. A Luxury or a Valuable Diagnostic Tool?
Inflammation & Allergy - Drug Targets (Discontinued) Prediction of MicroRNA–disease Associations by Matrix Completion
Current Proteomics Electrocardiographic and Cardiac Autonomic Indices - Implications of Sex-Specific Risk Stratification in Women After Acute Myocardial Infarction
Current Pharmaceutical Design Recent Patent in Controlled Porosity Osmotic Pump
Recent Patents on Drug Delivery & Formulation Recent Development and Future Prospects of Plant-Based Vaccines
Current Drug Metabolism Systemic Sclerosis: Clinical Manifestations
Current Rheumatology Reviews Vitamin D Supplementation: A Promising Approach for the Prevention and Treatment of Strokes
Current Drug Targets Neurodevelopmental Delay and Intellectual Disability in Pediatric Heart Transplant
Current Psychiatry Reviews Beta-Blockers: Effects on Bone Mineral Density and Fracture Risk
Current Rheumatology Reviews Immunomodulatory Actions of Vitamin D Metabolites and their Potential Relevance to Human Lung Disease
Current Respiratory Medicine Reviews Monogenic Diabetes: Genetics and Relevance on Diabetes Mellitus Personalized Medicine
Current Diabetes Reviews The Function of LncRNA FTX in Several Common Cancers
Current Pharmaceutical Design Treatment of Carotid Stenosis
Current Vascular Pharmacology <i>Thespesia populnea</i>: An Ethnomedicinal, Phytochemical and Pharmacological Review
The Natural Products Journal Fatty Acids in Marine Organisms: In the Pursuit of Bioactive Agents
Current Pharmaceutical Analysis The Causal Relationship Between Passive Smoking and Inflammation on the Development of Cardiovascular Disease: A Review of the Evidence
Inflammation & Allergy - Drug Targets (Discontinued) Randomized Clinical Stroke Trials in 2006
Current Vascular Pharmacology